Introduction and Objectives: In pancreatic islet cell transplantation, the early graft loss is due to the instant blood-mediated reaction (IBMIR). Control of early inflammatory events could improve the efficacy of islet cell transplantation and may enhance the long-term function of transplanted islets. Nanoencapsulation of islets is an attractive method for masking cell features that can trigger inflammatory cascades. Bissulfosuccinimidyl suberate (BS3) is a homobifunctional crosslinker with NHS ester on each side to bind to amine groups. Herein, we investigated the effects of BS3-modified human islets in terms of viability, function, longevity of modification, and inflammatory properties.

Methods: The surface of the human islets was modified with BS3 in different concentrations (0.5, 1, and 5 mM). Visual coverage and efficiency of surface conjugation were determined by incorporating an Amine-PEG-Biotin conjugate. Surface-conjugated islets were then cultured for 7 days. Visualization of conjugation and viability determination was performed days 0, 1, 4, and 7 of culture. The impact of BS3 conjugation on islet function was determined by measuring the oxygen consumption rates and glucose-stimulated insulin secretion.

Results: BS3 modification was found to be exceptionally biocompatible. The viability and functional integrity of islets were not altered at 0.5 mM and 1 mM BS3, but viability showed a mild decline at 5 mM BS3. However, improved conjugation of the islet surface and good coverage were noted in the 5 mM BS3 group. The surface modification was maintained for all 7 days tested with minimal loss of coverage. The markers of inflammation were examined using qPCR analysis. BS3 treated group showed higher inhibition of all pro-inflammatory genes under strong cytokine cocktail exposure.

Conclusion: Surface modification of islets with BS3 is a safe and tolerable approach that may be used for localized drug delivery strategies.

Disclosure

J. Kalivarathan: None. P. Saravanan: None. B.A. Fuglestad: None. S. Dhakal: None. S. Mohammed: None. M.F. Levy: None. M.A. Kanak: None.

Funding

Department of Defense (W81XWH2210102)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.